US · Healthcare

Kiniksa Pharmaceuticals Ltd (KNSA)

Drug Manufacturers - Specialty & Generic

Kiniksa Pharmaceuticals Ltd (KNSA) is listed on US in the Healthcare sector. Industry: Drug Manufacturers - Specialty & Generic. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for KNSA

P/E ratio

18.00

Kiniksa Pharmaceuticals Ltd (KNSA) — FAQ

What is KNSA's P/E ratio?

The price-to-earnings (P/E) ratio for Kiniksa Pharmaceuticals Ltd (KNSA) is 18.00 (data as of 2026-03-24).

Does Kiniksa Pharmaceuticals Ltd pay a dividend?

Dividend yield is not available in the current snapshot for Kiniksa Pharmaceuticals Ltd (KNSA). Check the MyAverix Finance app for the latest dividend data.

What sector is Kiniksa Pharmaceuticals Ltd in?

Kiniksa Pharmaceuticals Ltd (KNSA) is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

What exchange is KNSA listed on?

KNSA is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)